[ <font color="blue">Efficacy_1</font> <font color="blue">of_1</font> <font color="blue">paliperidone_1</font> <font color="blue">extended_1</font> <font color="blue">-_1</font> <font color="blue">release_1</font> <font color="blue">tablets_1</font> <font color="blue">in_1</font> <font color="blue">the_1</font> <font color="blue">improvement_1</font> <font color="blue">of_1</font> <font color="blue">social_1</font> <font color="blue">functions_1</font> in schizophrenics : a randomized and controlled study ] . 
<br>
<br> OBJECTIVE To explore the <font color="blue">efficacy_1</font> <font color="blue">of_1</font> <font color="blue">paliperidone_1</font> <font color="blue">extended_1</font> <font color="blue">-_1</font> <font color="blue">release_1</font> <font color="blue">tablets_1</font> <font color="blue">in_1</font> <font color="blue">the_1</font> <font color="blue">improvement_1</font> <font color="blue">of_1</font> <font color="blue">social_1</font> <font color="blue">functions_1</font> in schizophrenics . 
<br> METHODS A total of 81 schizophrenics were randomly divided into study group with paliperidone extended - release tablets and control group with risperidone for a 12-week treatment . They were assessed and analyzed by <font color="blue">positive_2</font> <font color="blue">and_2</font> <font color="blue">negative_2</font> <font color="blue">symptoms_2</font> <font color="blue">scales_2</font> <font color="blue">(_2</font> <font color="blue">PANSS_2</font> <font color="blue">)_2</font> <font color="blue">,_2</font> <font color="blue">social_1</font> <font color="blue">disability_1</font> <font color="blue">screening_1</font> <font color="blue">schedule_1</font> <font color="blue">(_1</font> <font color="blue">SDSS_1</font> <font color="blue">)_1</font> <font color="blue">and_1</font> <font color="blue">treatment_1</font> <font color="blue">emergent_1</font> <font color="blue">symptom_1</font> <font color="blue">scale_1</font> <font color="blue">(_1</font> <font color="blue">TESS_1</font> <font color="blue">)_1</font> at baseline , 6(th ) weekend and 12(th ) weekend . 
<br> RESULTS In study group , the <font color="blue">factors_2</font> <font color="blue">and_2</font> <font color="blue">total_3</font> <font color="blue">scores_3</font> <font color="blue">of_3</font> <font color="blue">PANSS_3</font> <font color="blue">in_1</font> <font color="blue">the_1</font> <font color="blue">12(th_1</font> <font color="blue">)_1</font> <font color="blue">weekend_1</font> <font color="blue">of_1</font> <font color="blue">treatment_1</font> [ ( 12.0 ± 2.8 ) , ( 12.1 ± 3.6 ) , ( 26.2 ± 5.0 ) , ( 50.2 ± 8.7 ) ] were all significantly lower than those at baseline [ ( 24.7 ± 5.3 ) , ( 23.8 ± 3.6 ) , ( 45.0 ± 2.9 ) , ( 93.5 ± 6.8 ) ] ( t = 9.60 - 16.78 , P < 0.05 ) . In study group , the <font color="blue">positive_2</font> <font color="blue">factor_2</font> <font color="blue">,_2</font> <font color="blue">negative_2</font> <font color="blue">factor_2</font> <font color="blue">and_2</font> <font color="blue">total_3</font> <font color="blue">scores_3</font> <font color="blue">of_3</font> <font color="blue">PANSS_3</font> <font color="blue">in_1</font> <font color="blue">the_1</font> <font color="blue">12(th_1</font> <font color="blue">)_1</font> <font color="blue">weekend_1</font> <font color="blue">of_1</font> <font color="blue">treatment_1</font> [ ( 12.0 ± 2.8 ) , ( 12.1 ± 3.6 ) , ( 50.2 ± 8.7 ) ] were all significantly lower than those in the 6(th ) weekend of treatment [ ( 14.2 ± 1.8 ) , ( 14.6 ± 2.4 ) , ( 56.5 ± 6.4 ) ] ( t = 2.58 - 4.26 , P < 0.05 ) . In the 12(th ) weekend of treatment , the <font color="blue">factors_2</font> <font color="blue">and_2</font> <font color="blue">total_3</font> <font color="blue">scores_3</font> <font color="blue">of_3</font> <font color="blue">PANSS_3</font> in study group [ ( 12.0 ± 2.8 ) , ( 12.1 ± 3.6 ) , ( 26.2 ± 5.0 ) , ( 50.2 ± 8.7 ) ] were all significantly lower than those in control group [ ( 16.9 ± 4.9 ) , ( 18.7 ± 5.3 ) , ( 32.5 ± 5.1 ) , ( 68.1 ± 13.0 ) ] ( t = -4.28 - -5.67 , P < 0.05 ) . In study group , the <font color="blue">total_2</font> <font color="blue">scores_2</font> <font color="blue">of_2</font> <font color="blue">SDSS_2</font> in the 12(th ) weekend of treatment ( 5.93 ± 2.78 ) were significantly lower than those at baseline ( 13.9 ± 3.4 ) ( t = 10.83 , P < 0.05 ) . In study group , the <font color="blue">total_3</font> <font color="blue">scores_3</font> <font color="blue">of_3</font> <font color="blue">SDSS_3</font> in the 12(th ) weekend of treatment ( 5.9 ± 2.8 ) were significantly lower than those in the 6(th ) weekend of treatment ( 7.6 ± 2.9 ) ( t = 5.21 , P < 0.05 ) . But there was <font color="blue">no_1</font> <font color="blue">significant_1</font> <font color="blue">improvement_1</font> in control group ( t = 1.88 , P > 0.05 ) . In the 12(th ) weekend of treatment , the <font color="blue">total_3</font> <font color="blue">scores_3</font> <font color="blue">of_3</font> <font color="blue">SDSS_3</font> in study group ( 5.9 ± 2.8 ) were significantly lower than those in control group ( 8.8 ± 2.9 ) ( t = -4.49 , P < 0.05 ) . <font color="blue">No_1</font> <font color="blue">severe_2</font> <font color="blue">adverse_2</font> <font color="blue">effect_2</font> was reported in either group . 
<br> CONCLUSION Paliperidone extended - release tablets are <font color="blue">effective_1</font> <font color="blue">to_1</font> <font color="blue">improve_1</font> <font color="blue">social_1</font> <font color="blue">functions_1</font> <font color="blue">and_1</font> <font color="blue">psychiatric_1</font> <font color="blue">symptoms_1</font> of schizophrenics .